Evgen Pharma (GB:TCF) has released an update.
TheraCryf plc, a clinical stage drug development company specializing in oncology and neuropsychiatry, announced successful passage of all resolutions at its recent AGM. With a diverse pipeline addressing various disorders including glioblastoma and narcolepsy, TheraCryf is focused on developing compelling data for its clinical programs and seeks partnerships for further trials and commercialization. The company is well-integrated with industry and academic institutions, leveraging collaborations to advance its research and development efforts.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.
